FRI0138 S100A12 and Calprotectin in Serum and The Aorta of Patients with Cardiovascular Disease and Inflammatory Rheumatic Disease: A Biopsy Study

BackgroundIncreased serum calprotectin (s-calprotectin) and S100A12 (s-S100A12) levels are associated with inflammatory rheumatic disease (IRD), and might be involved in the pathogenesis of cardiovascular disease (CVD).ObjectivesTo compare s-calprotectin and s-S100A12 levels in CVD patients with and without IRD, to IRD patients without CVD, and to healthy controls (HC). Furthermore, to search for relationships between s-calprotectin levels and calprotectin expression in the aortic adventitia.MethodsWe examined s-calprotectin and s-S100A12 in patients from the Feiring Heart Biopsy Study: 69 IRD (CVD-IRD group) and 53 non-IRD (CVD group) patients undergoing coronary artery bypass grafting (CABG), 32 IRD patients without any clinical or laboratory sign of CVD (IRD group) and 30 HC. Using immunohistochemistry, we scrutinized biopsies taken during CABG from the aortic adventitia in 19 CVD-IRD and 20 CVD patients for the presence and extent of inflammatory cell infiltrates (ICIs) and calprotectin expression.ResultsWe found no significant differences in levels of s-S100A12 between the four groups (p=0.56). There was not a significant difference in the calprotectin levels between the CVD-IRD and the IRD (1.30 vs 1.73 mg/l; p=0.16) groups. The groups with CVD (CVD and CVD-IRD) had significantly higher s-calprotectin level than the HC group (1.47 vs. 0.30 mg/l; p